About Eisai
Eisai is a company based in Tokyo (Japan) founded in 1941. The company has 10,920 employees as of March 31, 2024. Eisai has completed 3 acquisitions, including AkaRx, MGI Pharma and Morphotek. Eisai operates in a competitive market with competitors including Merck, AbbVie, Lilly, Roche and Novo Nordisk, among others.
- Headquarter Tokyo, Japan
- Employees 10920 as on 31 Mar, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Eisai Co., Ltd.
-
Annual Revenue
$5.28 B (USD)6.42as on Mar 31, 2025
-
Net Profit
$310.71 M (USD)9.49as on Mar 31, 2025
-
EBITDA
$596.59 M (USD)3.48as on Mar 31, 2025
-
Latest Funding Round
$947.65 K (USD), Grant
Mar 01, 2011
- Investors
-
Employee Count
10920
as on Mar 31, 2024
-
Investments & Acquisitions
AkaRx
& 2 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Eisai
Eisai is a publicly listed company on the TSE with ticker symbol 4523 in Japan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Eisai
Unlock access to complete
Unlock access to complete
Leadership Team
88 people
Software Development Team
34 people
Senior Team
29 people
Operations Team
29 people
Finance and Accounting
25 people
Human Resources and Administration
21 people
Data Analysis and Operations Team
21 people
Product Management Team
12 people
Unlock access to complete
Funding Insights of Eisai
Investors in Eisai
Eisai has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Eisai
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Eisai
Eisai has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include AkaRx, MGI Pharma and Morphotek.
Investment portfolio details for Eisai
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Limited information available
|
Locked | Locked | 2005 | Locked | |
|
Monoclonal antibodies against cancer, inflammatory and infectious diseases.
|
Locked | Locked | 2000 | Locked | |
|
Oncology and acute care pharmaceuticals are developed and commercialized.
|
Locked | Locked | 1979 | Locked |
Complete acquisition details for Eisai
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Eisai
Detailed financials for Eisai
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Eisai Comparisons
Peer comparison for Eisai
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Eisai
Eisai operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, AbbVie, Lilly, Roche and Novo Nordisk, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pharmaceutical products are manufactured and marketed worldwide.
|
|
| Locked | Locked | Locked |
Biopharmaceutical research and drug development are conducted globally by AbbVie.
|
|
| Locked | Locked | Locked |
Traditional pharmaceutical medicines are developed for multiple health fields.
|
|
| Locked | Locked | Locked |
Pharmaceuticals and diagnostics kits are developed for various diseases.
|
|
| Locked | Locked | Locked |
Drugs for diabetes, obesity, hemophilia, and hormone therapy are manufactured.
|
|
| Locked | Locked | Locked |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
|
Detailed competitors of Eisai
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Eisai
Complete news archive for Eisai
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Eisai
Eisai was founded in 1941 and raised its 1st funding round 66 years after it was founded.
Eisai is headquartered in Tokyo, Japan. It is registered at Tokyo, Tokyo, Japan.
Haruo Naito is the current CEO of Eisai.
As of Mar 31, 2024, the latest employee count at Eisai is 10,920.
Annual revenue of Eisai is $5.28B as on Mar 31, 2025.
Eisai was founded in 1941 in Tokyo, Japan, and operates in the pharmaceutical sector. Focus is placed on developing treatments for oncology and neurological conditions. Key products include rabeprazole for gastroesophageal reflux disease, risedronic acid for osteoporosis, palonosetron for chemotherapy-induced nausea, donepezil for Alzheimers disease, rufinamide for seizures in Lennox-Gastaut syndrome, lorcaserin for obesity, and dalteparin for deep vein thrombosis and pulmonary embolism. Global operations support drug development and distribution.
Eisai's top competitors include Merck, Roivant Sciences and Amgen.
Yes, Eisai is publicly traded on TSE under the ticker symbol 4523.
Eisai has made 3 acquisitions, including AkaRx, MGI Pharma, and Morphotek.
Eisai has 1 investor. Key investors include HHS.
The ticker symbol of Eisai is 4523 on TSE.